^
    Back
    Association details:
    Biomarker:HLA-DQB1*03:01
    Cancer:Small Cell Lung Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab-actl) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    IASLC-WCLC 2021
    Title:

    MA16.06 - Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN

    Published date:
    08/18/2021
    Excerpt:
    In CASPIAN, the presence of the HLA-DQB1*03:01 allele was associated with improved OS for durvalumab + tremelimumab + EP treatment.
    Secondary therapy:
    EP
    Trial ID:
    CASPIAN